
RRMM
Challenges in treatment of RRMM

Chief Medical Officer in Education, Kotka, Internal Medicine, Finland
Module 1: Optimizing treatment sequencing in RRMM
Accredited for 1 CME point
Module 2: Treating challenging RRMM patient subgroups
Accredited for 1 CME point
Module 3: Treatment implications and quality of life
Accredited for 1 CME point
Scientific Expert Panel

MD, PhD Inger Nijhof
Hematologist,
St. Antonius Hospital,
Department of Internal Medicine,
The Netherlands

MD, PhD Fredrik Schjesvold
Hematologist,
Oslo Myeloma Center,
Department of Hematology,
Norway

MD, PhD Isabelle Vande Broek
Hematologist,
Vitaz, Sint-Niklaas,
Department of Oncology & Hematology,
Belgium

MD Agoston Gyula Szabo
Hematologist,
Righospitalet Copenhagen,
Department of Hematology,
Denmark

MD, PhD Ville Varmavuo
Chief Medical Officer in Education,
Kotka,
Internal Medicine,
Finland

MD, PhD Prof. Xavier Leleu
Hematologist,
Academic Hospital of Poitiers,
France

MD Valdas Peceliunas
Hematologist,
Vilnius University Hospital Santaros Klinikos,
Department of Hematology,
Lithuania
Accreditation
Accreditation for this e-learning has been granted for 1 point per module by:
European Accreditation Council for Continuing Medical Education (EACCME)
Obtain CME points
To obtain CME points, you must answer at least 70% of the questions in the final test correctly. If you have a lower score, you can retake the final test twice more. You can pause the e-learning and then resume where you paused.
Clinical cases
Throughout the e-learning challenging clinical cases from daily practice are being presented by the International Expert Panel.